Skip to main content

Advertisement

SpringerLink
Log in

Donor-Derived Disease Transmission in Lung Transplantation

  • Lung Transplant (R Bag, Section Editor)
  • Published:
Current Pulmonology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Understanding the risk of donor-derived infection, particularly in the lung transplant population, should reduce discarding organs without risk. Ongoing regulatory efforts and improved clinician awareness can help improve organ supply and post-transplantation outcomes.

Recent Findings

Infections can be divided into expected and unexpected. Syndromes that manifest in the early-post-transplant period should raise concern of a donor-derived transmission. Emerging data suggests that donors with certain bacterial infections can be safely used while donors with HCV infection can be a useful source of previously discarded organs.

Summary

Donor-derived disease transmission events are rare. Thoughtful donor and recipient screening can mitigate the risk of disease transmission through organ transplantation and may identify donor organs that can be safely used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation. Thirty-fifth adult lung and heart-lung transplant report-2019; Focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1169.

    PubMed  Google Scholar 

  2. •• Seem DL, Lee I, Umscheid CA, Kuehnert MJ, United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep. 2013;128(4):247–343 In this paper, the updated PHS guidelines for defining and testing donors at increased risk of HIV, HBV and HCV transmission are reviewed.

    PubMed  PubMed Central  Google Scholar 

  3. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11(6):1123–30.

    CAS  PubMed  Google Scholar 

  4. Garzoni C, Ison MG. Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. Transplantation. 2011;92(12):1297–300.

    PubMed  Google Scholar 

  5. Ison MG, Hager J, Lumber E, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9(8):1929–35.

    CAS  PubMed  Google Scholar 

  6. • MRP S, Jones JM, Bowman J, Levi ME, Basavaraju SV. Impact of US Public Health Service increased risk deceased donor designation on organ utilization. Am J Transplant. 2019;19(9):2560–9 This paper reviews the utilization of PHS increased risk donors in the United States. Of note, underutilization of these donors was noted among lung transplant centers nationally.

    Google Scholar 

  7. Bansal S, Hayanga J, Odell J, Odell D, Jeong K, Fabio A, et al. Risky business: taking the stigma out of high-risk donation in lung transplantation. Ann Thorac Surg. 2015;100(5):1787–93.

    PubMed  Google Scholar 

  8. •• Wolfe CR, Ison MG, AST Infectious Diseases Community of Practice. Donor-derived infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;23:e13547 This is the current AST ID Community of Practice guideline for evaluating and screening for donor-derived infections.

    Google Scholar 

  9. Grewal AS, Padera RF, Boukedes S, DIvo M, Rosas IO, Camp PC, et al. Prevalence and outcome of lung cancer in lung transplant recipients. Respir Med. 2015;109(3):427–33.

    PubMed  Google Scholar 

  10. Minai OA, Shah S, Mazzone P, Budev MM, Sahoo D, Murthy S, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol. 2008;3(12):1404–9.

    PubMed  Google Scholar 

  11. De Soyza AG, Dark JH, Parums DV, Curtis A, Corris PA. Donor-acquired small cell lung cancer following pulmonary transplantation. Chest. 2001;120(3):1030–1.

    PubMed  Google Scholar 

  12. Beyer EA, DeCamp MM, Smedira NG, Farver C, Mehta A, Warshawsky I. Primary adenocarcinoma in a donor lung: evaluation and surgical management. J Heart Lung Transplant. 2003;22(10):1174–7.

    PubMed  Google Scholar 

  13. Schwarz EI, Vrugt B, Huber LC, Murer C, Schuurmans MM, Inci I, et al. Development of allograft Cancer after lung transplantation: a case report. Ann Thorac Cardiovasc Surg. 2017;23(4):196–9.

    PubMed  PubMed Central  Google Scholar 

  14. Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003;22(11):1183–200.

    PubMed  Google Scholar 

  15. Zaas AK, Alexander BD. New developments in the diagnosis and treatment of infections in lung transplant recipients. Respir Care Clin N Am. 2004;10(4):531–47.

    PubMed  Google Scholar 

  16. Ruiz I, Gavaldá J, Monforte V, Len O, Román A, Bravo C, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6(1):178–82.

    CAS  PubMed  Google Scholar 

  17. Malinis M, Boucher HW, AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13548.

    PubMed  Google Scholar 

  18. Lanini S, Costa AN, Puro V, Procaccio F, Grossi PA, Vespasiano F, et al. Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study. PLoS One. 2015;10(4):e0123706.

    PubMed  PubMed Central  Google Scholar 

  19. Ziakas PD, Pliakos EE, Zervou FN, Knoll BM, Rice LB, Mylonakis E. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant. 2014;14(8):1887–94.

    CAS  PubMed  Google Scholar 

  20. Bert F, Larroque B, Dondero F, Durand F, Paugam-Burtz C, Belghiti J, et al. Risk factors associated with preoperative fecal carriage of extended-spectrum ß-lactamase-producing Enterobacteriaceae in liver transplant recipients. Transpl Infect Dis. 2014;16(1):84–9.

    CAS  PubMed  Google Scholar 

  21. Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancy. Clin Infect Dis. 2014;58(9):1274–83.

    PubMed  PubMed Central  Google Scholar 

  22. Wu TJ, Lee CF, Chou HS, Yu MC, Lee WC. Suspect the donor with potential infection in the adult deceased donor liver transplantation. Transplant Proc. 2008;40(8):2486–8.

    PubMed  Google Scholar 

  23. Goldberg E, Bishara J, Lev S, Singer P, Cohen J. Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report. Transpl Infect Dis. 2012;14(3):296–9.

    CAS  PubMed  Google Scholar 

  24. Martins N, Martins IS, de Freitas WV, de Matos JA, Magalhães AC, Girão VB, et al. Severe infection in a lung transplant recipient caused by donor-transmitted carbapenem-resistant Acinetobacter baumannii. Transpl Infect Dis. 2012;14(3):316–20.

    CAS  PubMed  Google Scholar 

  25. Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, et al. Outcome of transplantation using organs from donors infected or colonized with carbapenem-resistant gram-negative Bacteria. Am J Transplant. 2015;15(10):2674–82.

    CAS  PubMed  Google Scholar 

  26. Wendt JM, Kaul D, Limbago BM, Ramesh M, Cohle S, Denison AM, et al. Transmission of methicillin-resistant Staphylococcus aureus infection through solid organ transplantation: confirmation via whole genome sequencing. Am J Transplant. 2014;14(11):2633–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. • Errico G, Gagliotti C, Monaco M, Masiero L, Gaibani P, Ambretti S, et al. Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy. Clin Microbiol Infect. 2019;25(2):203–9 In this paper, the authors look at incidence of CRE transmission through organ donation in a high prevalence area (Italy).

    CAS  PubMed  Google Scholar 

  28. Bharat A, Cunningham SA, Scott Budinger GR, Kreisel D, DeWet CJ, Gelman AE, et al. Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med. 2015;7(284):284.re3.

    Google Scholar 

  29. Fernandez R, Ratliff A, Crabb D, Waites KB, Bharat A. Ureaplasma transmitted from donor lungs is pathogenic after lung transplantation. Ann Thorac Surg. 2017;103(2):670–1.

    PubMed  Google Scholar 

  30. McLaughlin DC, Mallea JM, Ng LK. Hyperammonemia presenting as refractory status epilepticus after lung transplant in a patient positive for Ureaplasma parvum. Indian J Crit Care med. 2018;22(6):463–5.

    PubMed  PubMed Central  Google Scholar 

  31. Matson KM, Sonetti DA. Successful treatment of Ureaplasma-induced hyperammonemia syndrome post-lung transplant. Transpl Infect Dis. 2019;21(1):e13022.

    PubMed  Google Scholar 

  32. Somerville L, Sligl W, Zelyas N, Lien D, Preiksaitis J. Surveillance for mycoplasma/Ureaplasma infection in lung transplant recipients (LTRs). Am J Transplant. 2017;17(suppl 3).

  33. Roberts SC, Bharat A, Kurihara C, Bhorade S, Ison MG. Donor-derived Ureaplasma infection increases mortality in lung transplant recipients. Poster presented at IDWeek; 2–6 October 2019; Washington DC. http://www.idweek.org.

  34. Miranda C, Camacho E, Reina G, Turiño J, Rodríguez-Granger J, Yeste R, et al. Isolation of mycoplasma hominis from extragenital cultures. Eur J Clin Microbiol Infect Dis. 2005;24(5):334–7.

    CAS  PubMed  Google Scholar 

  35. Sampath R, Patel R, Cunningham S, Arif S, Daly RC, Badley AD, et al. Cardiothoracic transplant recipient mycoplasma hominis: an uncommon infection with probable donor transmission. EBioMedicine. 2017;19:84–90.

    PubMed  PubMed Central  Google Scholar 

  36. Ho M. Epidemiology of cytomegalovirus infection. Rev Infect Dis. 1990;12(Suppl 7):S701.

    PubMed  Google Scholar 

  37. Delforge ML, Desomberg L, Montesinos I. Evaluation of the new LISASON (®) CMV IgG, IgM, and IgG avidity II assays. J Clin Virol. 2015;72:42–5.

    CAS  PubMed  Google Scholar 

  38. Lagrou K, Bodeus M, Van Ranst M, Goubau P. Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J Clin Microbiol. 2009;47:1695–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. •• Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danzinger-Isakov L, et al. The third international consensus guildelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–31 Updated international guidelines on the diagnosis and management of CMV in the SOT population.

    PubMed  Google Scholar 

  40. •• Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients—guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512 Updated AST IDCOP guidelines on CMV disease in the SOT population.

    PubMed  Google Scholar 

  41. Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013;207(1):80–8.

    CAS  PubMed  Google Scholar 

  42. Wudhikarn K, Holman CJ, Linan M, Blaes AH, Dunitz JM, Hertz ME, et al. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota. Clin Transpl. 2011;25(5):705–13.

    Google Scholar 

  43. Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, et al. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. J Heart Lung Transplant. 2012;31(3):296–304.

    PubMed  Google Scholar 

  44. Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015;15(10):2665–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1712–7.

    CAS  PubMed  Google Scholar 

  46. Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol. 2003;69(2):258–66.

    PubMed  Google Scholar 

  47. Hirama T, Tikkanen J, Pal P, Cleary S, Binnie M. Epstein-Barr virus-associated smooth muscle tumors after lung transplantation. Transpl Infect Dis. 2019;21(3):e13068.

    PubMed  Google Scholar 

  48. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.

    CAS  PubMed  Google Scholar 

  49. OPTN Policy 2.0 Deceased donor organ procurement (Policy 2.9). Organ Procurement and Transplant Network (OPTN). (2018). https://optn.transplant.hrsa.gove/medial/1200/optn_policies.pdf. Accessed 05 September 2019.

  50. Echenique IA, Ison MG. Update on donor-derived infections in liver transplantation. Liver Transpl. 2013;19:575–85.

    PubMed  Google Scholar 

  51. Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33(9):e13514.

    Google Scholar 

  52. Ouseph R, Eng M, Ravinda K, Brock GN, Buell JF, Marvin MR. Review of the use of hepatitis B core antibody-positive kidney donors. Transplant Rev. 2010;24:167–71.

    Google Scholar 

  53. Danzinger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13563.

    Google Scholar 

  54. Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine. 1993;11:397–9.

    CAS  PubMed  Google Scholar 

  55. Feuerhake A, Muller R, Lauchart W, Pichlmayr R, Schmidt FW. HBV-vaccination in recipients of kidney allografts. Vaccine. 1984;2:255–6.

    CAS  PubMed  Google Scholar 

  56. Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162–72.

    CAS  PubMed  Google Scholar 

  57. • Kucirka LM, Sarathy H, Govindan P, Wolf JH, Elllison TA, Hart LJ, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1188–200 This study reviewed the existing literature and used meta-analysis to estimate the residual risk of HCV infection in donors with risk factors.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–802.

    CAS  PubMed  Google Scholar 

  59. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999;117(1):149–53.

    CAS  PubMed  Google Scholar 

  60. Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shakad A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation. 2002;73(4):582–7.

    PubMed  Google Scholar 

  61. Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23(10):1038–44.

    PubMed  Google Scholar 

  62. Cotter TG, Paul S, Sandıkçı B, Couri T, Bodzin AS, Little EC, et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-Viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors. Hepatology. 2019;69:2381.

    CAS  PubMed  Google Scholar 

  63. Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, et al. National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys. J Am Soc Nephrol. 2019;30(10):1939–51.

    PubMed  Google Scholar 

  64. •• Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med. 2019;380(17):1606–17 Landmark study that demonstrated safety and efficacy of pre-emptive therapy to treat thoracic transplant patients who were recipients of HCV NAT positive donors.

    PubMed  Google Scholar 

  65. Ison MG, Llata E, Conover CS, Friedewald JJ, Gerber SI, Grigoryan A, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant. 2011;11:1218–25.

    CAS  PubMed  Google Scholar 

  66. Villa E, Nanni CA. HIV-positive organs used for transplant in Italy due to human error. Euro Surveill. 2007;12:E0703081.

    Google Scholar 

  67. CDC. HIV transmitted from a living organ donor—New York City, 2009. MMWR Morb Mortal Wkly Rep. 2011;60:297–301.

    Google Scholar 

  68. OPTN Guidance on explaining risk related to use of U.S. PHS increased risk donor organs when considering organ offers. Organ Procurement and Transplantation Network (OPTN). (2017). https://optn.transplant.hrsa.gov/media/2171/dtac_boardreport_201706.pdf. Accessed 15 September 2019.

  69. • Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1176–87 This study reviewed the existing literature and used meta-analysis to estimate the residual risk of HIV infection in donors with risk factors.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Kern RM, Seethamraju H, Blanc PD, Sinha N, Loebe M, Golden J, et al. The feasibility of lung transplantation in HIV-seropositive patients. Ann Am Thorac Soc. 2014;11(6):882–9.

    PubMed  PubMed Central  Google Scholar 

  71. Bertani A, Grossi P, Vitulo P, D’Ancona G, Arcadipane A, Nanni Costa A, et al. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. Am J Transplant. 2009;9(9):2190–6.

    CAS  PubMed  Google Scholar 

  72. Ong S, Levy RD, Yee J, Partovi N, Churg A, Roméo P, et al. Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report. BMC Pulm Med. 2018;18(1):162.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Blumberg EA, Rogers CC, American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13499.

    PubMed  Google Scholar 

  74. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816–20.

    CAS  PubMed  Google Scholar 

  75. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Mazuecos A, Fernandez A, Andres A, Gomez E, Zarraga S, Burgos D, et al. HIV infection and renal transplantation. Nephrol Dialysis Transplant. 2011;26:1401–7.

    Google Scholar 

  77. Baccarani U, Adani GL, Bragantini F, Londero A, Comuzzi C, Rossetto A, et al. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc. 2011;43:1119–2.

    CAS  PubMed  Google Scholar 

  78. Organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. Final rule. Fed Regist. 2015;80:26464–7.

  79. Nash D, Mostashari F, Fine A, Miller J, O’Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344:1807.

    CAS  PubMed  Google Scholar 

  80. Centers for Disease Control and Prevention. West Nile virus transmission via organ transplantation and blood transfusion—Louisiana, 2008. MMWR. 2009;58:1263–7.

    Google Scholar 

  81. Singh N, Levi ME. Arenavirus and West Nile virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):361–71.

    CAS  PubMed  Google Scholar 

  82. Freifeld AG, Mez J, Schweitzer B, Shafer L, Kalil AC, Sambol AR. Seroprevalence of West Nile virus infection in solid organ transplant recipients. Transplant Infect Dis. 2010;12:120–6.

    CAS  Google Scholar 

  83. Hazell SL. Serological diagnosis of West Nile virus. http://www2.mlo-online.com/archives/articles/0604/0604coverstory.pdf. 2004.

  84. Centers for Disease Control and Prevention. Update: investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion. MMWR. 2002;51:833–6.

    Google Scholar 

  85. • Anesi JA, Silveira FP, AST Infectious Diseases Community of Practice. Arenaviruses and West Nile Virus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13576 Updated guidelines from the AST IDCOP for West Nile Virus in SOT recipients.

    PubMed  Google Scholar 

  86. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis. 2002;8:107–8.

    PubMed  PubMed Central  Google Scholar 

  87. Jackson AC. Therapy of West Nile virus infection. Can Neurol Sci. 2004;31:131–4.

    Google Scholar 

  88. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235–49.

    CAS  PubMed  Google Scholar 

  89. Centers for Disease Control and Prevention. Brief report: lymphocytic choriomeningitis virus transmitted through solid organ transplantation—Massachusetts, 2008. MMWR Morb Mortal Wkly Rep. 2008;57(29):799–801.

    Google Scholar 

  90. Amman BR, Pavlin BI, Albariño CG, Comer JA, Erickson BR, Oliver JB, et al. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg Infect Dis. 2007;13(5):719–25.

    PubMed  PubMed Central  Google Scholar 

  91. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352(11):1103–11.

    CAS  PubMed  Google Scholar 

  92. Maier T, Schwarting A, Mauer D, Ross RS, Martens A, Kliem V, et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis. 2010;50(8):1112–9.

    CAS  PubMed  Google Scholar 

  93. Zhou H, Zhu W, Zeng J, He J, Liu K, Li Y, et al. Probable rabies virus transmission through organ transplantation, China, 2015. Emerg Infect Dis. 2016;22(8):1348–52.

    PubMed  PubMed Central  Google Scholar 

  94. • CLR A, Razonable RR. Donor-derived Mycobacterium tuberculosis infection after solid-organ transplantation: a comprehensive review. Transpl Infect Dis. 2018;20(5):e12971 One of the largest reviews of donor-derived Mycobacterium tuberculosis infection in SOT.

    Google Scholar 

  95. Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid-organ transplantation: a review of more than 2000 cases. Clin Transpl. 2018;32:e13259.

    Google Scholar 

  96. Azar MM, Turbett SE, Fishman JA, Pierce VM. Donor-derived transmission of Candida auris during lung transplantation. Clin Infect Dis. 2017;65(6):1040–2.

    PubMed  Google Scholar 

  97. Centers for Disease Control Prevention Recommendations for treatment of Candida auris. http://www.cdc.gov/fungal/diseases/candidiasis/c-auris-treatment.html. Accessed 5 September 2019.

  98. Corey AB, Sonetti D, Maloney JD, Montgomery SP, Rademacher BL, Taylor LJ, et al. Transmission of donor-derived Trypanosoma cruzi and subsequent development of Chagas disease in a lung transplant recipient. Case Rep Infect Dis. 2017;2017:538107.

    Google Scholar 

  99. Kun H, Moore A, Mascola L, Steurer F, Lawrence G, Kubak B, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis. 2009;48(11):1534–40.

    PubMed  Google Scholar 

  100. Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001-2011. Am J Transplant. 2013;13(9):2418–25.

    CAS  PubMed  Google Scholar 

  101. •• La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13618 Updated guidelines on intestinal parasites in SOT.

    PubMed  Google Scholar 

  102. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis. 2009;49(9):1411–23.

    PubMed  PubMed Central  Google Scholar 

  103. Kim JH, Kim DS, Yoon YK, Sohn JW, Kim MJ. Donor-derived Strongyloidiasis infection in solid organ transplant recipients: a review and pooled analysis. Transplant Proc. 2016;48(7):2442–9.

    CAS  PubMed  Google Scholar 

  104. Abanyie FA, Gray EB, Delli Carpini KW, Yanofsky A, McAuliffe I, Rana M, et al. Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009-2013. Am J Transplant. 2015;15(5):1369–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Buonfrate D, Perandin F, Formenti F, Bisoffi Z. A retrospective study comparing agar plate culture, indirect immunofluorescence and real-time PCR for the diagnosis of Strongyloides stercoralis infection. Parasitology. 2017;144(6):812–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Infectious Diseases, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue Suite 900, Chicago, IL, 60611, USA

    Scott C. Roberts & Michael G. Ison

  2. Organ Transplantation, Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue Suite 900, Chicago, IL, 60611, USA

    Michael G. Ison

Authors
  1. Scott C. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael G. Ison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael G. Ison.

Ethics declarations

Conflict of Interest

Michael Ison reports personal fees from Shionogi, personal fees from Celltrion, grants and personal fees from Genetech/Roche, grants and personal fees from Janssen, personal fees from Seqirus, personal fees from Viracor Eurofins, personal fees from VirBio, grants from Emergent BioSolutions, during the conduct of the study, and Payments to Northwestern University by AiCuris, Chimerix, Gilead, and Shire for research. He reports being a non-paid consultant for GlaxoSmithKlein, Romark, and Vertex.

Scott Roberts declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lung Transplant

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roberts, S.C., Ison, M.G. Donor-Derived Disease Transmission in Lung Transplantation. Curr Pulmonol Rep 9, 1–9 (2020). https://doi.org/10.1007/s13665-020-00245-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13665-020-00245-z

Keywords

Search

Navigation